SCHEMBL6715746

SCHEMBL6715746

O=C(Nc1ccccc1Cl)C(c1ccccc1)N(S)C(=O)Nc1ccccc1[N+](=O)[O-]

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.53
KMT2A Q03164 5/20 0.51
RAB9A P51151 2/20 0.45
NPC1 O15118 1/20 0.45
PHGDH O43175 1/20 0.44
KCNQ2 O43526 1/20 0.44
MEN1 O00255 4/20 0.44
MAPT P10636 4/20 0.44
CYP2C9 P11712 2/20 0.44
CYP2C19 P33261 2/20 0.44
NPSR1 Q6W5P4 2/20 0.44
CYP2D6 P10635 1/20 0.44
CASR P41180 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
MAPK1 P28482 1/20 0.42
ALDH1A1 P00352 2/20 0.42
XBP1 P17861 1/20 0.42
HTT P42858 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6717198 0.89 LMNA (0.50) LMNAKMT2ARAB9ANPC1PHGDH
SCHEMBL6717353 0.88 PHGDH (0.50) LMNAKMT2APHGDHMEN1MAPT
SCHEMBL6713814 0.87 KMT2A (0.49) LMNAKMT2AMEN1MAPTCYP2C9
SCHEMBL6716840 0.87 KMT2A (0.49) LMNAKMT2AMEN1MAPTCYP2C9
SCHEMBL6714420 0.86 RAB9A (0.53) LMNAKMT2ARAB9ANPC1MEN1
SCHEMBL6717130 0.86 MAPT (0.46) LMNAKMT2ARAB9ANPC1KCNQ2
SCHEMBL6717165 0.86 MAPT (0.54) LMNAKMT2ARAB9ANPC1PHGDH
SCHEMBL6716800 0.85 LMNA (0.45) LMNAKMT2AMEN1MAPTCYP2C9
SCHEMBL6716955 0.85 KMT2A (0.45) LMNAKMT2ARAB9AMEN1MAPT
SCHEMBL6717147 0.85 KMT2A (0.44) LMNAKMT2ARAB9ANPC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors SLC1A2, SLC6A7, SLC1A1 LMNA 3700/4885KMT2A 2020/4885RAB9A 2094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.